Q2 earnings slide for Spherix
BETHESDA, Md. Revenues for drug maker Spherix fell in second quarter 2010 and for the first six months of the year, according to financial data released this week.
Spherix, which develops drugs for diabetes and metabolic disorders, reported second-quarter revenues of $327,139, compared with $332,241 in second quarter 2009. Revenues for the first six months of 2010 were $659,430, compared with $692,911 last year. That translated into a net loss of $2.56 million for the quarter and $4.7 million for the first half of the year.
Spherix also announced plans to release efficacy results from a late-stage clinical trial of its D-tagatose compound in patients with Type 2 diabetes in mid-September, and is looking for a drug company to be its development partner. The company also is investigating the drug, which it acquired from the University of Kentucky Research Foundation, as a treatment for high triglycerides.
New mobile application keeps pharmacy customers in touch
FORT WORTH, Texas Pharmacy technology company PDX and mobile application maker Acclaim Telecom Services will integrate Acclaim’s Smart Mobile RX application with PDX pharmacy systems.
The integration will allow pharmacies to reach patients through text messages, emails and voice reminders regarding refills and other services. The product will be shown at the National Association of Chain Drug Stores’ Pharmacy and Technology Conference in San Diego later this month.
“By partnering with PDX, Acclaim’s Smart Mobile RX can be rapidly deployed by pharmacies across the spectrum of mobile phones in use by consumers,” Acclaim president James Davis said in a statement. “Pharmacy smart phone customers have the added benefit of downloading a branded mobile application from their respective phone providers’ application store.”
Richard Salazar joins Pharmacy First’s Rx$hare program
OVERLAND PARK, Kan. A national network of retail community pharmacies has named a new manufacturer contracting director for a retail program designed to generate significant, incremental revenue for such businesses.
Pharmacy First announced Monday that Richard Salazar would join its Rx$hare program. Salazar will be responsible for all manufacturer contracts and programs under the Rx$hare program banner, which include market share programs, awareness programs, launch programs and Compliance Services, a direct-mail, patient-focused adherence model.
Prior to joining Pharmacy First, Salazar was national director of Rx and business development for AmerisourceBergen for six years.
“Clearly, with the retail pharmacy arena changing so quickly, we needed a person who knows the terrain and has contacts throughout the pharma industry. Additionally, we needed a person who understands the value of making and maintaining solid business relationships,” said Brian Huckle, Wholesale Alliance/Pharmacy First CEO. “Our board of directors is excited about getting someone like Rick to join our team, and we remain extremely excited about the opportunities available for independent pharmacies, and the solutions Pharmacy First offers to them.”